Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

6 Oct 2022

Abstract excerpt

Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment and precludes standardization. Allogeneic off-the-shelf CAR-T cells are an alternative to simplify this complex and time-consuming process. Here we investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36275777
DOI: 10.3389/fimmu.2022.1011858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphomaPMID 36275777Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity Read ↗

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read ↗

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read ↗

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read ↗

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?Semantic proximity Read ↗

CAR T-cell Therapy: A New Era in Cancer ImmunotherapySemantic proximity Read ↗

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaSemantic proximity Read ↗

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art reviewSemantic proximity Read ↗

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read ↗

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cellsSemantic proximity Read ↗

A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modelingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.